Background
Introduction
Tuberculosis ranks among the leading causes of morbidity and mortality worldwide [1] . The World Health Organization (WHO) targets to eliminate tuberculosis as a public health problem by the year 2050 [2] . Unfortunately, lack of efficient screening tests for the identification of persons latently infected with Mycobacterium tuberculosis (LTBI), the delay in the diagnosis of active disease and the emergence of drug resistant strains of M. tuberculosis [3] are among the causes that jeopardize the achievement of the goal to eliminate tuberculosis in the near future. The most accessible tool for the diagnosis of LTBI is the tuberculin skin test, which has a very low specificity [4] , and does not differentiate between M. tuberculosis sensitization and non-tuberculous mycobacterial (NTM) infections or history of M. bovis Bacille Calmette Guérin (BCG)-vaccination. Interferon-γ release assays (IGRA) represent an alternative to tuberculin skin tests and have emerged during the last decade as reference diagnostics for LTBI [5] . IGRAs measure the interferon (IFN)-γ release after stimulation of blood cells with M. tuberculosis-specific antigens [6] . Despite the fact that this new tool can differentiate between M. tuberculosis and NTM infections or M. bovis BCG-vaccination, IGRAs still fail to distinguish between active tuberculosis and LTBI [7] . Following tuberculosis, positive IGRA test results can persist in the absence of active disease. Recent publications suggest that the accuracy in discriminating LTBI from active tuberculosis can be improved by parallel assessment of the secreting profile of T-cells for other cytokines, such as interleukin (IL)-2 and/or tumor necrosis factor (TNF)-α [8] [9] [10] [11] [12] . Nevertheless, the clinical usefulness of this approach still needs to be investigated and this has so far mainly been addressed using flow-cytometry [10, 12, 13] that represents the technical gold standard for multiparameter analysis of immune cells. However, flow cytometry analysis is expensive and labour-intensive. The two colour FluoroSpot (AID, Straß-berg, Germany) is a novel Enzyme-linked-immuno-Spot (EliSpot) technology, which enables to simultaneously assesses individual cells that secret M. tuberculosis-induced cytokines IFN-γ and IL-2 [11] . The FluoroSpot is cheaper and easier to perform than flow cytometer analysis [12] .
We evaluated whether the analysis of dual (IFN-γ and IL-2) cytokine profile analysis by FluoroSpot is superior to the EliSpot-IGRA technology to distinguish between different states of M. tuberculosis infection.
Participants and Methods

Study participants
Following written informed consent patients with suspected tuberculosis or a documented history of previous tuberculosis from the Medical Clinic of the Research Center Borstel, Germany, and healthy controls, were recruited between December 2011 and December 2013.
Seventy-one participants were Caucasian, one patient with tuberculosis and another study participant with former tuberculosis were of Asian origin. All patients were tested negative for infection with human immunodeficiency virus 1. At the time of analysis 2/18 patients with tuberculosis had been on anti-tuberculosis treatment for a short period of time (<7% of their whole treatment duration).
Twenty mL venous peripheral blood was obtained and tested for the M. tuberculosis-specific immune response by EliSpot-IGRA (T-Spot.TB, Oxford Immunotec, Abingdon (UK) and FluoroSpot (AID, Straßberg, Germany) test systems. The four different study groups were defined as follows: 1) The diagnosis of tuberculosis was based on a positive M. tuberculosis culture result or a positive M. tuberculosis-specific nucleic amplification assay from sputum or a bronchopulmonary specimen, irrespective of EliSpot-IGRA test result. 2) Past tuberculosis was defined as diagnosed, treated and cured tuberculosis. Treatment had to be finished one year before the inclusion date. Inclusion was independent of the EliSpot-IGRA result. If reactivation of tuberculosis was suspected at admission, clinical data, imaging and a negative culture result had to exclude active disease. 3) Individuals with LTBI were defined by a positive response in the EliSpot-IGRA in individuals without any signs of tuberculosis disease [14] . 4) Healthy controls were volunteers with no history or sign of tuberculosis and a negative EliSpot-IGRA test result.
Ethics Statement
The study was approved by the Ethical Committee of the University of Lübeck, Germany (05-096 and 12-072A). Written informed consent was obtained from all study participants. Reporting follows the STARD guidelines.
Detection of IL-2 + and IFN-γ + secreting cells
The cytokine response was studied on peripheral blood mononuclear cells (PBMC) isolated by Ficoll Hypaque density gradient centrifugation (Biochrom, Berlin, Germany). Duplicates of 200.000 cells per well were cultured overnight in 200 μL RPMI 1640 (PAA Laboratoris GmbH, Pasching, Austria) enriched with 5% fetal bovine serum (PAA Laboratoris GmbH, Pasching, Austria) on precoated 96-well plates. The EliSpot-IGRA assay was performed on T-Spot.TB plates from Oxford Immunotec Ltd., Abingdon, UK, the FluoroSpot assay was performed on FluoroSpot plates from AID, Straßberg, Germany. As recommended by the manufacturer, in the FluoroSpotassay all cells were cultured with anti-CD28 (0.5 μg/mL, AID, Straßberg, Germany). Unstimulated PBMC were used as negative control, PBMC stimulated with anti-CD3 (10ng/mL, clone X35, Beckman Coulter GmbH, Krefeld, Germany) for the EliSpot-IGRA and FluoroSpot, additionally pokeweed mitogen (PWM, 5μg/mL, Biochrom AG, Berlin, Bielefeld) served as positive control for the FluoroSpot. In both, the EliSpot-IGRA and FluoroSpot, specific stimulation was performed with the M. tuberculosis-specific antigens early secreted antigenic target 6 kDA (ESAT-6) and culture filtrate protein 10 kDA (CFP-10), 50 μL each, in a ready to use format from Oxford Immunotec. After 18 hours of culture the washing and staining procedures were performed as previously described for FluoroSpot [11] or according to the manufacturer's instructions for EliSpot-IGRA [15] . Both, EliSpot-IGRA and FluoroSpot spots were counted with the AID EliSpot reader and software. Cytokine producing cells were expressed as number of spot-forming cells (SFC). The background response of the negative control was always deducted from specifically stimulated wells.
EliSpot-IGRA assay results were considered positive if more than five net SFC were counted after ESAT-6 or CFP-10 stimulation, and if the total number of SFC after specific stimulation was at least twice the number of SFC in the negative control well. EliSpot-IGRA results were considered negative if they did not meet the definition for a positive result and if the number of SFC in the positive control well was more than 20 SFC after subtraction of the number of spots in the negative control well and had at least twice the number of spots of the negative control well. Results that did not meet the criteria of positive or negative were considered indeterminate [16] .
For a correct interpretation of the FluoroSpot, the positive controls anti-CD3 or pokeweed mitogen (PWM) had to induce more than 50 SFC/well of IL-2 + and more than 50 SFC/well IFN-γ + secreting cells after subtraction of the number of spots in the negative control well and at least twice the number of spots of the negative control well, otherwise the test was assessed as indeterminate [11] . Providing a valid positive control result, the net SFC counts after ESAT-6 or CFP-10 stimulation was used as a continuous variable for each cytokine.
The performance of the EliSpot-IGRA and FluoroSpot was assessed for the accuracy of differentiation between the three different states of M. tuberculosis infection (active disease, past tuberculosis, LTBI) and healthy controls with negative EliSpot-IGRA results and agreement of both tests results between them. Culture results in the case of tuberculosis, EliSpot-IGRA results in the case of LTBI, healthy controls or past tuberculosis were used as reference standard. 
Statistical analysis
For comparative analysis between groups the Mann-Whitney U-test for nonparametric data was used. Statistical tests for paired data were performed by Wilcoxon Signed Rank test. A pvalue of <0.05 was considered significant. Concordance between EliSpot-IGRA and FluoroSpot results were assessed using R 2 coefficient. Bland-Altman test was used to figure the agreement between EliSpot-IGRA and FluoroSpot, calculating the mean difference (FluoroSpot-Eli Spot-IGRA/69) and the 95% limits of agreement (average difference ± 1.96 standard deviation of the difference) [17] . Receiver operator characteristics (ROC) analyses were performed to establish cutoffs of ESAT-6 and CFP-10-reactive cells producing the different cytokine combinations. The cutoff with the highest diagnostic sensitivity and specificity was determined using Youden index statistics. All statistical analyses were performed using the sixth version of GraphPad Prism (GraphPad Software, La Jolla, California, USA).
Results
A total of 73 recruited for this study. Four patients with suspected tuberculosis were excluded due to the final diagnosis a of lung disease other than tuberculosis (two patients with bronchial carcinoma, one pleuropneumonia, one disseminated pulmonary infection with M. caprae).
The clinical characteristics of the 69 eligible participants and their corresponding EliSpot-IGRA results are depicted in Fig. 1 , the demographical characteristics are shown in Table 1 . All 18 persons with active pulmonary tuberculosis had clinical and radiological findings consistent with tuberculosis and a positive EliSpot-IGRA immune response to at least one of the M. tuberculosis-specific antigens. Only one patient had a negative M. tuberculosis culture, but due to a positive nucleic acid amplification test and as both of his parents had positive cultures for M. tuberculosis, the patient was classified as a tuberculosis patient. In detail, 13 out of 18 patients with tuberculosis were positive by EliSpot-IGRA for both ESAT-6 and CFP-10, four patients reacted towards CFP-10 only and one patient was positive for ESAT-6 only (Fig. 1) . Among the ten individuals with past tuberculosis, one had negative EliSpot-IGRA results for both ESAT-6 and CFP-10, whereas six individuals reacted towards ESAT-6 and eight individuals responded to CFP-10. In the LTBI group 24 out of 25 individuals had a positive ESAT-6 response and 22 a positive CFP-10 response. The 16 healthy controls had negative EliSpot-IGRA results.
As expected, neither ESAT-6 ( Fig. 2A) nor CFP-10-induced IFN-γ response in the EliSpot-IGRA (Fig. 2B ) allowed the discrimination between the different infection states of tuberculosis, past tuberculosis or LTBI. 
Concordance between EliSpot-IGRA and FluoroSpot assays results
Assessment of IL-2 and IFN-γ response induced by CFP-10 using FluoroSpot assay
The 
Clinical utility of EliSpot-IGRA and FluoroSpot test systems
The comparison of the receiver operator characteristics (ROC) analysis of EliSpot-IGRA and FluoroSpot revealed that the CFP-10-specific IFN-γ-response in EliSpot-IGRA performed as best discriminator between patients with active tuberculosis and persons with past TB, LTBI, or healthy controls (Fig. 4 and Table 2 
Discussion
This study was performed to evaluate the potential of the additional assessment of IL-2 secreting T-cells to IGRAs to overcome limitations of IGRAs in the differentiation of different states with EliSpot-IGRA results [12] . In contrast to previously published data [12] and despite the use of anti-CD28 as co-stimulatory antibody during the overnight cell culture in the FluoroSpot test system, FluoroSpot had very low background reactivity and SFC counts were lower than those obtained using EliSpot-IGRA. ROC analysis of the FluoroSpot SFC data revealed ESAT-6 = early secreted antigenic target 6 kDA.
CFP-10 = culture filtrate protein 10 kDA. IL-2 = Interleukin-2.
IFN-γ = Interferon gamma.
-= negative for cytokine production. + = positive for cytokine production. [8, 11-13, 19, 21] are not confirmed by our findings. However, the results of cytokine profiling to distinguish between tuberculosis and LTBI are unequivocal [22, 23] . Some groups found that tuberculin purified protein derivative induced IL-2 + IFN-γ + secreting cells effectively discriminate between active tuberculosis and non-active states, butsimilar to our results-these differences were not observed for T-cells specific for ESAT-6 and CFP-10 [13] . Instead, others proved differences in ESAT-6/CFP-10-induced T-cell cytokine profiles between subjects with active and cured tuberculosis [8] and LTBI [12] . Discrepancy could have several reasons: different test assays (flow cytometry, ELISA-IGRA, EliSpot-IGRA, FluoroSpot), as well as different antigens preparations [18] and differences in protocols, e. g. prolonged time of incubation seems to account for differences due to increased cytokine secretion [19, 24, 25] . Disparities in study subjects' characteristics might be caused by different exposure to mycobacteria in high or low incidence countries of tuberculosis as well as differences in bacterial load in disease; e.g. smear positivity was reported to decrease polyfunctional cytokine immune response [26] . Furthermore, the variation might just be due to inter-individual magnitude of immune responses. In order to adjust for this inter-individual variability of immune responses we have suggested to express individual cytokine response as proportion of the overall specific immune response of the individual values of IL-2 + IFN-γ -, IL-2 -IFN-γ + , IL-2 + IFN-γ + responses to improve the differentiation of the M. tuberculosis infection states [11] .
In our previous study a three-marker-model of the different cytokine-producing subpopulations, expressed as percentage of all cells producing these cytokines, has improved the discrimination of LTBI from active tuberculosis patients. In our present study this approach did not increase discrimination. Our study has several limitations: The lack of IL-2 assessment by an IL-2 specific EliSpot-IGRA reduces the strength of the comparison between EliSpot-IGRA and FluoroSpot. In retrospect, the stimulation with tuberculin purified protein derivative antigen would have allowed broader comparison with results from other studies regarding differences between cytokine profiles of T-cells with specificity for ESAT-6/ CFP-10 and tuberculin [8, 13] .
In conclusion, antigen-specific IL-2 -IFN-γ + secreting T-cells are elevated in active tuberculosis in comparison to past tuberculosis and LTBI and can be easily identified by FluoroSpot. However, parallel diagnostic of IL-2 and IFN-γ secretion by antigen-specific T-cells does not allow a reliable differentiation between different states of M. tuberculosis infection in clinical practice.
